SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amplify Commodity Trust - Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF is drawing attention as investors weigh the impact of regional conflicts and geopolitical instability on global tanker logistics and shipping rates. The community is debating whether the current price action reflects a structural shift in maritime capacity or temporary volatility driven by the escalating situation near critical chokepoints.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML Holding NV is currently trending as investors weigh strong AI-driven demand and a record backlog against potential headwinds from new U.S. export controls and broader semiconductor market volatility. Community sentiment remains mixed, with bullish long-term investors pointing to the company's EUV lithography monopoly, while others express caution regarding valuation premiums and geopolitical risks impacting the global supply chain.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is trending as investors monitor bank earnings and the rollout of new credit default swaps tied to private credit, while the firm also navigates internal scrutiny regarding historical ties to Jeffrey Epstein. The community is actively debating the firm's leadership, potential staff reductions, and its role in managing major upcoming deals like the SpaceX IPO.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as the community leans into its legacy as a long-standing parody project, with supporters highlighting its early origins and the goal of achieving billion-dollar status. Discussion centers on the project's shift from a joke to an on-chain asset, with the community actively comparing its potential to the broader cryptocurrency market while leveraging the humor inherent in its branding.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing intense volatility as the market digests the fallout from stalled negotiations in the Strait of Hormuz, with community sentiment deeply divided between fears of further geopolitical escalation and optimism for a broader crypto recovery. While some traders are bracing for a potential downturn due to rising energy costs and macro uncertainty, others are actively tracking ETF inflows and technical indicators for signs of a sustained breakout.

Maulcoin

Maulcoin is capturing market attention as its community pushes to achieve significant milestones, including plans for upcoming airdrops for verified holders. Investors are actively discussing the coin's organic growth and the potential for long-term value appreciation, fueling a strong sense of momentum among those committed to holding the asset.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is gaining significant traction as the community rallies around the restoration of iconic internet meme tools, positioning the asset as a culture-driven project rather than a typical speculative coin. Supporters are actively engaging in 'bag working' and meme creation, fueled by a collective belief in the historical significance of the original Rage Guy character.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is gaining community momentum as supporters highlight the project's strategic token supply locks and upcoming one-year anniversary. Investors are expressing high conviction, focusing on the brand's pivot toward viral positivity-themed content and a long-term commitment to ecosystem growth.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is currently trending as the community leans into its legacy as a cultural meme, with active discussions focusing on its historical origins in rage comics and its expanding presence across the Solana ecosystem. Investors are comparing it to other established meme coins, emphasizing the strength of its community "diamond hands" and its potential for long-term growth as part of a broader "culture coin" narrative.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is generating intense community debate as investors weigh its potential for a supply-driven rally against frustration over its prolonged underperformance relative to other DeFi protocols. While some traders point to the coin's capped supply and ongoing governance developments as catalysts for a rebound, many voices express skepticism, highlighting persistent downward pressure and the competitive dominance of alternatives like AAVE.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

Equity

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.


Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for positive reasons.Trinity Biotech (<a href="https://stocktwits.com/symbol/TRIB">TRIB</a>)&nbsp;Shares of the medical diagnostic products maker saw a staggering 15,550% jump in retail message volume after the company released “compelling” results from a study on its next-generation continuous glucose monitoring system.&nbsp;The device, designed for real-time diabetes management, demonstrated superior signal quality, accuracy, and consistency in a trial involving 30 diabetic participants.&nbsp;The system features a reusable applicator and rechargeable wearable transmitter, reducing costs by eliminating disposable components.&nbsp;Trinity said it remains on track to seek regulatory approval in the EU by 2025 and the U.S. by 2026.&nbsp;Shares fell over 13% premarket Wednesday.Silexion Therapeutics (<a href="https://stocktwits.com/symbol/SLXN">SLXN</a>)&nbsp;The cancer-focused biotech firm’s ticker saw a 9,060% surge in retail message volume as its stock more than doubled Tuesday following promising preclinical data for its tumor drug candidate SIL-204.&nbsp;The company reported that the extended-release formulation of SIL-204 reduced tumor growth by more than 50% after 30 days, with around 50% of tumors showing complete necrosis in human pancreatic models.&nbsp;Additionally, an injectable version of the drug candidate showed tumor growth inhibition in metastatic pancreatic mouse models.&nbsp;The stock continued its rally, gaining over 70% premarket Wednesday.Sharps Technology (<a href="https://stocktwits.com/symbol/STSS">STSS</a>)&nbsp;The medical packaging firm experienced a 6,233% surge in retail message volume, but for the wrong reasons.&nbsp;Shares plunged nearly 70% to a record low on Tuesday after the company announced a $20 million public offering of 14,285,714 Common Units.&nbsp;Each unit consists of one share of common stock, one Series A warrant, and one Series B warrant, priced at $1.40 per unit, a 4.1% discount to Monday’s close.&nbsp;The company said the proceeds would be used for general corporate purposes and working capital.&nbsp;The stock continued to slide, down over 2% premarket Wednesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%

“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.

Shares of Silexion Therapeutics lost&nbsp;more than a quarter of their market capitalization on Thursday morning, hitting a record intraday low after the company priced a $5 million public offering late Wednesday.The stock is also on track for its worst day since Dec. 26.The offering includes approximately 3.7 million ordinary shares and accompanying warrants for&nbsp;purchasing up to 3.7 million additional shares.&nbsp;Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.&nbsp;The warrants, which will expire five years from issuance, carry an exercise price of $1.35 and are exercisable immediately. The offering is expected to close on Friday.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SLXN_sentiment_and_message_volume_Jan_16_ebe16b64bc.png" alt="SLXN sentiment and message volume Jan 16.png" width="1318" height="324"><figcaption>SLXN sentiment and message volume Jan 16 as of 10 am ET | source: Stocktwits</figcaption></figure>Despite the steep decline in share price, retail sentiment for Silexion was ‘extremely bullish’ on Stocktwits, where message volume surged to a six-month high.&nbsp;Some users voiced plans to buy shares once the offering concludes, while others noted the company’s low float, available cash, and technical levels as reasons for cautious optimism.<stembedurl>https://stocktwits.com/Kevin_Gough/message/600264740</stembedurl><stembedurl>https://stocktwits.com/Patience__/message/600239429</stembedurl><stembedurl>https://stocktwits.com/StockProphercy/message/600293377</stembedurl>Fueling this sentiment further is Wednesday’s release of encouraging preclinical data for Silexion’s experimental pancreatic cancer treatment, SIL-204.&nbsp;According to the company, SIL-204 demonstrated strong synergistic effects when combined with common chemotherapeutic agents, including 5-fluorouracil, irinotecan, and gemcitabine, in human cell lines with KRAS G12D mutations, the most prevalent type of pancreatic cancer.Silexion said it plans to initiate toxicology studies for SIL-204 within the next few months, with phase 2/3 clinical trials scheduled for the first half of 2026.&nbsp;Financially, Silexion ended the third quarter of 2024 with cash and equivalents totaling $2 million and debt near $230,000, according to Koyfin.&nbsp;However, the stock has lost over 98% of its value in the past year, reflecting challenges that may&nbsp;affect its prospects.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures

Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.

The market’s resilience came under test on Wednesday as apprehensions ahead of earnings from artificial intelligence stalwart Nvidia Corp. (<a class="mention" data-mention="$NVDA" data-symbol-id="NVDA" href="https://stocktwits.com/symbol/NVDA" target="_blank">$NVDA</a>) generated some weakness early in the session.Nvidia stock was last seen trading down more than 1%, giving back some of the nearly 5% gain it made on Wednesday.As traders look ahead to the company’s market-moving&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-stalwart-nvidia-to-report-q3-2025-results-wednesday/cJ4UNCxRQC">earnings report,</a> due after the market close, here is a compilation of the most bullish stocks on Stocktwits:Forte Biosciences, In. (<a class="mention" data-mention="$FBRX" data-symbol-id="FBRX" href="https://stocktwits.com/symbol/FBRX" target="_blank">$FBRX</a>)&nbsp;Forte Biosciences shares were last seen rallying over 170% as the nano-cap autoimmune disorders-focused clinical-stage biopharma said its equity financing to support the continuing clinical advancement of its lead candidate FB102 was oversubscribed. “ As a result of the financing, Forte is well capitalized to continue advancing FB102 across autoimmune indications,” it added.Quantum-Si Inc. (<a class="mention" data-mention="$QSI" data-symbol-id="QSI" href="https://stocktwits.com/symbol/QSI" target="_blank">$QSI</a>):Shares of Quantum-Si, a medical-device company that develops a single-molecule detection platform to enable next-gen protein sequencing (NGPS), more than doubled on Wednesday on volumes that are notably above their 3-month average.The upside came after the company made a slew of announcements. Quantum-Si said Avantor, Inc. (<a class="mention" data-mention="$AVTR" data-symbol-id="AVTR" href="https://stocktwits.com/symbol/AVTR" target="_blank">$AVTR</a>) will distribute its NGPS portfolio, providing researchers across the U.S. and Canada access to the portfolio.In a separate release, Quantum-Si announced a collaboration with Nvidia to develop its next proteomics platform called Proteus and advance its core technologies of amino acid binders and amino peptidases using Nvidia AI and accelerated computing.&nbsp;Quantum-Si also announced an expanded partnership with SkyWater Technology, Inc. (<a class="mention" data-mention="$SKYT" data-symbol-id="SKYT" href="https://stocktwits.com/symbol/SKYT" target="_blank">$SKYT</a>) for developing Proetus and a separate deal with its contract manufacturing partner Planet Innovation for the same.&nbsp;Silexion Therapeutics Corp. (<a class="mention" data-mention="$SLXN" data-symbol-id="SLXN" href="https://stocktwits.com/symbol/SLXN" target="_blank">$SLXN</a>)Silexion, a clinical-stage biotech developing RNA interference therapies for certain types of cancers, disclosed in a filing on Tuesday that at the reconvened extraordinary general meeting, its shareholders approved the board recommendation for a reverse split of the shares in the ratio 1-for-9.&nbsp;The penny stock climbed 33% on Wednesday on above-average volume.Duos Technologies Group, Inc. (<a class="mention" data-mention="$DUOT" data-symbol-id="DUOT" href="https://stocktwits.com/symbol/DUOT" target="_blank">$DUOT</a>)Shares of Jacksonville, Florida-based Duos Tech, a software services provider, climbed over 17% after the company announced the signing of a $42 million worth of asset management agreement with Fortress Investment Group to deploy and operate a fleet of mobile gas turbines and balance-of-plant inventory that has a combined generation capacity of 850 megawatts.ZIM Integrated Shipping Services Ltd. (<a class="mention" data-mention="$ZIM" data-symbol-id="ZIM" href="https://stocktwits.com/symbol/ZIM" target="_blank">$ZIM</a>)Cargo shipping firm ZIM Integrated reported <a href="https://stocktwits.com/news-articles/markets/equity/zim-integrated-shipping-stock-rises-premarket-after-strong-q3-earnings/cJ46SQoRXc">upbeat third-quarter earnings</a> and raised its full-year guidance, sending its shares higher by over 7%. Retail hoped for large buyers increasing their exposure to the stock, sending it to the $31-$32 area by the close.<stembedurl>https://stocktwits.com/View2021/message/593365202</stembedurl>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q3-2025-earnings-imminent/cJ46Z2LRXE">Nvidia Stock Slips Ahead Of Earnings: Gene Munster Explains Why Blackwell Chip Demand Commentary Is Important For Investors</a>

US Stocks dipped ahead of Nvidia earnings but a few sent retailers into a tizzy. 

5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The company was founded on November 30, 2008 and is headquartered in in Modiin, Israel.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$3.40	-$2.88	15.29%	BEAT
Q2 '25	-$3.15	-$4.32	-37.14%	MISSED
Q1 '25	-$0.22	-$3.90	-1672.73%	MISSED
Q4 '24	-$0.98	--	--	N/A
Q3 '24	-$0.82	--	--	N/A

SLXN
Silexion Therapeutics Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest SLXN News

SLXNSilexion Therapeutics Ltd